Mayo Clinic Minute: Understanding, treating lymphoma
Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. The main two subtypes are Hodgkin lymphoma and non-Hodgkin lymphoma. Because of breakthrough research, this once fatal diagnosis has been transformed into a curable condition. In this Mayo Clinic Minute, Dr. Stephen Ansell, a Mayo Clinic hematologist, discusses the [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 30, 2021 Category: Databases & Libraries Source Type: news
Cancer symptoms: Painless swellings may be a sign of non-Hodgkin lymphoma
CANCER will affect one in two of us, meaning 50 percent of the British population will get the deadly disease in their lifetime. What are the early warning signs of non-Hodgkin lymphoma? (Source: Daily Express - Health)
Source: Daily Express - Health - March 24, 2021 Category: Consumer Health News Source Type: news
What Is the Survival Rate for NonHodgkin Lymphoma
What Is the Survival Rate for Non-Hodgkin Lymphoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 24, 2021 Category: General Medicine Source Type: news
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
SOUTH SAN FRANCISCO, Calif., March 22, 2021 -- (Healthcare Sales & Marketing Network) -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering... Biopharmaceuticals, Oncology, Personnel Sutro Biopharma, XpressCF+, multiple myeloma, non-Hodgkin lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2021 Category: Pharmaceuticals Source Type: news
Penn-developed CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma
(University of Pennsylvania School of Medicine) A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah , researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 17, 2021 Category: Cancer & Oncology Source Type: news
First Data for CAR T-cell Therapy in Follicular Lymphoma First Data for CAR T-cell Therapy in Follicular Lymphoma
The ZUMA-5 results show impressive responses for patients with refractory/relapsed indolent non-Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Steroids Increase Infection Risk With CAR T-Cell Therapy in NHL Steroids Increase Infection Risk With CAR T-Cell Therapy in NHL
Steroids and multiple prior treatments markedly increase the risk of infection following CAR T-cell therapy in patients with high-grade B-cell non-Hodgkin ' s lymphoma, UK clinicians have found.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
ASH: CAR T-Cell Therapy Promising for Relapsed/Refractory iNHL
WEDNESDAY, Dec. 9, 2020 -- Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, is promising for the treatment of relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 9, 2020 Category: Pharmaceuticals Source Type: news
New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained in patien...
Source: Roche Media News - December 7, 2020 Category: Pharmaceuticals Source Type: news
New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained in patien...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news
CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma
(Dana-Farber Cancer Institute) A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2020 Category: International Medicine & Public Health Source Type: news
Hodgkin's vs. Non-Hodgkin's Lymphoma
Title: Hodgkin ' s vs. Non-Hodgkin ' s LymphomaCategory: Diseases and ConditionsCreated: 1/31/2007 12:00:00 AMLast Editorial Review: 11/10/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 10, 2020 Category: Cancer & Oncology Source Type: news
Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to developing...
Source: Roche Media News - November 5, 2020 Category: Pharmaceuticals Source Type: news
Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to developing...
Source: Roche Investor Update - November 5, 2020 Category: Pharmaceuticals Source Type: news
14.10.20: Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's LymphomaPhase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adu...
Source: Bayer IR Newsfeed: Events - October 14, 2020 Category: Pharmaceuticals Source Type: news
